Arjen H G Cleven

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4154263/publications.pdf

Version: 2024-02-01

38	1,177	567281 15	395702 33
papers	citations	h-index	g-index

38	38	38	2405
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ossifying Fibroma of Non-odontogenic Origin: A Fibro-osseous Lesion in the Craniofacial Skeleton to be (Re-)considered. Head and Neck Pathology, 2022, 16, 257-267.	2.6	9
2	Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 671-675.	2.8	3
3	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. Nature Communications, 2021, 12, 3361.	12.8	19
4	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775.	5.2	11
5	NTRK fusions are extremely rare in bone tumours. Histopathology, 2021, 79, 880-885.	2.9	7
6	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. Sarcoma, 2021, 2021, 1-6.	1.3	4
7	Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing. Leukemia and Lymphoma, 2021, , 1-5.	1.3	2
8	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Modern Pathology, 2020, 33, 404-419.	5.5	80
9	Molecular findings in maxillofacial bone tumours and its diagnostic value. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 159-174.	2.8	17
10	Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 455-463.	2.8	44
11	Multiple pleomorphic dermal sarcomas with metastases in an immunosuppressed patient. Dermatologic Therapy, 2020, 33, e13441.	1.7	1
12	Bâ€cell lymphoblastic lymphoma with cutaneous involvement and a <scp>KMT2A</scp> gene rearrangement. American Journal of Hematology, 2020, 95, 1427-1429.	4.1	5
13	Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2020, 44, 776-781.	3.7	25
14	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood, 2019, 134, 946-950.	1.4	18
15	Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis. Histopathology, 2019, 75, 843-852.	2.9	13
16	Primary Osteosarcoma of the Breast. Radiographics, 2019, 39, 626-629.	3.3	14
17	Corresponding anaplastic lymphoma kinaseâ€“tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus. JAAD Case Reports, 2019, 5, 970-972.	0.8	4
18	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. Frontiers in Immunology, 2019, 10, 3045.	4.8	4

#	Article	IF	Citations
19	High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype. Blood, 2019, 134, 1484-1484.	1.4	0
20	High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood, 2018, 131, 2086-2089.	1.4	69
21	Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. British Journal of Cancer, 2018, 118, 1074-1083.	6.4	37
22	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. OncoImmunology, 2018, 7, e1386828.	4.6	36
23	Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCRâ€“Based Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2018, 20, 653-663.	2.8	85
24	<scp>ARTISAN PCR</scp>: rapid identification of fullâ€length immunoglobulin rearrangements without primer binding bias. British Journal of Haematology, 2017, 178, 983-986.	2.5	28
25	Current Pathologic Scoring Systems for Metal-on-metal THA Revisions are not Reproducible. Clinical Orthopaedics and Related Research, 2017, 475, 3005-3011.	1.5	5
26	Hematopoietic Tumors Primarily Presenting in Bone. Surgical Pathology Clinics, 2017, 10, 675-691.	1.7	9
27	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clinical Sarcoma Research, 2017, 7, 8.	2.3	50
28	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 119-128.	4.2	89
29	An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 957-966.	2.3	11
30	Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging. Journal of the American Society for Mass Spectrometry, 2017, 28, 376-383.	2.8	37
31	<scp>DOG</scp>1 expression in giantâ€cellâ€containing bone tumours. Histopathology, 2016, 68, 942-945.	2.9	13
32	No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. BMC Cancer, 2016, 16, 475.	2.6	7
33	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. Endocrine, 2016, 54, 642-647.	2.3	8
34	High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. Clinical Sarcoma Research, 2016, 6, 17.	2.3	4
35	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology, 2016, 29, 582-590.	5.5	164
36	Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology, 2015, 67, 483-490.	2.9	29

#	Article	IF	Citations
37	Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. American Journal of Surgical Pathology, 2015, 39, 1576-1583.	3.7	174
38	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Pathology, 2015, 28, 552-563.	5.5	42